relugolix
Systemic hormonal preparations (H01)US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
pharma · Prostate Cancer
Myovant Sciences
Myovant Sciences GmbH
Myovant Sciences drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Myovant Sciences pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Myovant Sciences drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.